Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang
Questions loom as to whether Allergan's pair of CGRP antagonists will face the liver toxicity issues that previously plagued oral CGRP drugs. The firm is counting on the migraine therapies to help offset revenues lost to generics.
You may also be interested in...
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.
Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.
Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.